DK1255536T3 - Indolinonderivater til modulation af c-kit-tyrosinproteinkinase - Google Patents

Indolinonderivater til modulation af c-kit-tyrosinproteinkinase

Info

Publication number
DK1255536T3
DK1255536T3 DK00991704T DK00991704T DK1255536T3 DK 1255536 T3 DK1255536 T3 DK 1255536T3 DK 00991704 T DK00991704 T DK 00991704T DK 00991704 T DK00991704 T DK 00991704T DK 1255536 T3 DK1255536 T3 DK 1255536T3
Authority
DK
Denmark
Prior art keywords
modulation
protein kinase
tyrosine protein
kit tyrosine
indolinone derivatives
Prior art date
Application number
DK00991704T
Other languages
Danish (da)
English (en)
Inventor
Gerald Mcmahon
Ken Lipson
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22624773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1255536(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK1255536T3 publication Critical patent/DK1255536T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK00991704T 1999-12-22 2000-12-22 Indolinonderivater til modulation af c-kit-tyrosinproteinkinase DK1255536T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17169399P 1999-12-22 1999-12-22

Publications (1)

Publication Number Publication Date
DK1255536T3 true DK1255536T3 (da) 2006-10-30

Family

ID=22624773

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00991704T DK1255536T3 (da) 1999-12-22 2000-12-22 Indolinonderivater til modulation af c-kit-tyrosinproteinkinase

Country Status (15)

Country Link
US (3) US20020010203A1 (fr)
EP (1) EP1255536B1 (fr)
JP (1) JP5004392B2 (fr)
AT (1) ATE331514T1 (fr)
AU (1) AU784266B2 (fr)
CA (1) CA2395461C (fr)
CY (1) CY1106165T1 (fr)
DE (1) DE60029138T2 (fr)
DK (1) DK1255536T3 (fr)
ES (1) ES2267605T3 (fr)
HK (1) HK1050642A1 (fr)
MX (1) MXPA02006263A (fr)
NZ (1) NZ519697A (fr)
PT (1) PT1255536E (fr)
WO (1) WO2001045689A2 (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2248981C (fr) * 1996-03-15 2009-11-24 The Penn State Research Foundation Detection d'acide nucleique extracellulaire lie a des tumeurs dans le plasma ou le serum sanguin a l'aide d'essais d'amplification d'acide nucleique
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
AU3977001A (en) * 2000-02-15 2001-08-27 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors
AU2001295986B2 (en) * 2000-10-20 2006-08-17 Eisai R&D Management Co., Ltd Nitrogenous aromatic ring compounds
WO2003002114A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de c-kit puissants, selectifs et non toxiques dans le traitement de la mastocytose
WO2003002105A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
JP2005502614A (ja) * 2001-06-29 2005-01-27 アブ サイエンス 多発性硬化症（ｍｓ）を治療するためのチロシンキナーゼ阻害剤の使用方法
WO2003003006A2 (fr) * 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
EP1401412A2 (fr) * 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
ATE401079T1 (de) * 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
CA2452392A1 (fr) * 2001-06-29 2003-01-16 Ab Science Utilisation d'inhibiteurs de tyrosine kinases pour traiter les maladies intestinales inflammatoires (mii)
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
WO2003002106A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de maladies allergiques
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US7419777B2 (en) * 2001-08-21 2008-09-02 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
EP1461032B1 (fr) * 2001-09-20 2008-07-16 AB Science Utilisation d'inhibiteurs de la c-kit pour stimuler la pousse des cheveux
DE60228278D1 (de) * 2001-09-20 2008-09-25 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
EP1450775B1 (fr) * 2001-09-20 2008-03-12 AB Science Inhibiteurs de c-kit pour traiter des infections bacteriennes
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
EP1439834A1 (fr) * 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindoles hydrazides modulateurs des proteines tyrosines phosphatases (ptps)
CN1308326C (zh) 2002-02-15 2007-04-04 法马西亚和厄普乔恩公司 吲哚满酮衍生物的制备方法
CA2477111A1 (fr) * 2002-02-27 2003-09-04 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de troubles du snc
EP1347041A1 (fr) * 2002-03-21 2003-09-24 Universitätsklinikum Benjamin Franklin der Freien Universität Berlin Lignée cellulaire de mammifères independantes des facteurs de croissance et une méthode pour sa préparation
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
WO2004080462A1 (fr) * 2003-03-10 2004-09-23 Eisai Co., Ltd. Inhibiteur de kinase c-kit
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
WO2006001954A2 (fr) * 2004-05-20 2006-01-05 Puget Sound Blood Center And Program Procedes favorisant la formation de plaquettes et permettant le traitement de troubles du sang et de la moelle osseuse
US20060058339A1 (en) * 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
BRPI0610066A2 (pt) * 2005-05-17 2010-05-25 Plexxikon Inc compostos que modulam atividade de c-kit e c-fms e usos para estes
CN102603581B (zh) * 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
WO2007015569A1 (fr) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. Procédé de prédiction de l’efficacité d’un inhibiteur de vascularisation
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CA2620594C (fr) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Composition pharmaceutique dotee d'une meilleure capacite a se desintegrer
NZ566033A (en) * 2005-09-19 2011-04-29 Pfizer Prod Inc Solid salt forms of a pyrrole substituted 2-indolinone
NZ568385A (en) 2005-10-21 2012-07-27 Univ California C-kit oncogene mutations in melanoma
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CA2652442C (fr) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Agent antitumoral destine au cancer de la thyroide
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
AU2007275682B2 (en) 2006-07-20 2012-05-17 Amgen Inc. Substituted pyridone compounds and methods of use
CA2658190C (fr) 2006-07-20 2013-01-29 Amgen Inc. Composes heterocycliques a bi-substitution amino et procedes d'utilisation
US8048411B2 (en) * 2006-08-17 2011-11-01 The Cleveland Clinic Foundation Co-transplantation of hepatic stellate cells and islet cells
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
AU2007296740B2 (en) * 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2008079909A1 (fr) * 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008080001A2 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et procédés pour la modulation de kinases et indications pour celle-ci
CA2676796C (fr) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition destinee au traitement d'un cancer de l'estomac de type indifferencie
WO2008138184A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2068152A1 (fr) 2007-12-06 2009-06-10 Max-Delbrück-Centrum für Molekulare Medizin (MDC) c-Kit en tant que nouvelle cible pour le traitement de la douleur
CA2713930A1 (fr) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Utilisation combinee d'un inhibiteur de l'angiogenese et d'un taxane
EP2090306A1 (fr) 2008-02-13 2009-08-19 Ratiopharm GmbH Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (fr) 2008-04-29 2009-11-04 Ratiopharm GmbH Composition pharmaceutique comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-dimethyl-1H-pyrrole-3-carboxamide
EP2098521A1 (fr) 2008-03-06 2009-09-09 Ratiopharm GmbH Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide
EP2138167A1 (fr) 2008-06-24 2009-12-30 ratiopharm GmbH Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8993615B2 (en) 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
CR20170089A (es) 2009-04-03 2017-07-17 Plexxikon Inc Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
CN101885698B (zh) * 2009-05-15 2012-07-11 浙江海正药业股份有限公司 一种吡咯基丙烯酰胺类化合物及其在舒尼替尼合成中的应用
EP2255792A1 (fr) 2009-05-20 2010-12-01 Ratiopharm GmbH Composition pharmaceutique pour n-[2-(diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1h-pyrrole-3-carboxamide
EP2264027A1 (fr) 2009-05-27 2010-12-22 Ratiopharm GmbH Processus pour la préparation de N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011057022A1 (fr) 2009-11-06 2011-05-12 Plexxikon, Inc. Composés et méthodes de modulation des kinases et leurs indications d'emploi
US20120289571A1 (en) * 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2011119777A2 (fr) 2010-03-23 2011-09-29 The Johns Hopkins University Compositions et méthodes de traitement d'une maladie neurodégénérative
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
US20120076797A1 (en) * 2010-07-14 2012-03-29 Butte Atul J Modulation of kit signaling and hematopoietic cell development by IL-4 receptor modulation
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
WO2012068487A1 (fr) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Présélection de patients pour un traitement thérapeutique fondé sur un état hypoxique, avec des agents sensibles à l'oxygène
WO2012068549A2 (fr) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Formulations d'agents thérapeutiques pour des dispositifs implantés
EP2654797B1 (fr) 2010-12-23 2017-11-08 Nektar Therapeutics Conjugués polymère-dés-éthyl sunitinib
US9827326B2 (en) 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012103165A2 (fr) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anticorps anti-kit et leurs utilisations
RS58455B1 (sr) 2011-02-07 2019-04-30 Plexxikon Inc Jedinjenja i postupci za modulaciju kinaze, i indikacije za njih
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US8630703B2 (en) 2011-03-09 2014-01-14 Technion Research & Development Foundation Limited Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
EP2714937B1 (fr) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
EP2739252A4 (fr) 2011-08-05 2015-08-12 Forsight Vision4 Inc Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP4063391A1 (fr) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
CN104981247A (zh) 2012-09-06 2015-10-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US20150297593A1 (en) * 2012-09-14 2015-10-22 Children's Medical Center Corporation Inhibition of viral infection-triggered asthma with c-kit inhibitor
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
SG10201707095QA (en) 2012-12-21 2017-09-28 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2014152959A1 (fr) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US10450295B2 (en) * 2013-08-09 2019-10-22 Acclaim BioMed USA LLC Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10239943B2 (en) * 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
KR20170040798A (ko) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
IL302218B1 (en) 2014-08-28 2024-06-01 Eisai R&D Man Co Ltd Methods for the production of lanvotinib and its derivatives in a high degree of purity
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016184793A1 (fr) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr
EP3311841B1 (fr) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Agent anticancéreux
BR112018005589A2 (pt) 2015-09-22 2018-10-09 Graybug Vision Inc “composto, composição farmaceuticamente aceitável, e, uso de um composto”
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
WO2018209155A1 (fr) 2017-05-10 2018-11-15 Graybug Vision, Inc. Microparticules à libération prolongée et suspensions de celles-ci destinées à une thérapie médicale
WO2023081923A1 (fr) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Inhibiteurs du récepteur du facteur de croissance dérivé des plaquettes (pdgfr) alpha et leurs utilisations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
CA2102780C (fr) 1991-05-10 2007-01-09 Alfred P. Spada Composes de type bis-monoaryle, aryle bicyclique et (ou) heteroaryle inhibant l'activite de tyrosine kinase des recepteurs de l'egf et (ou) du pdgf
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
WO1994003427A1 (fr) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) et disulfures associes (seleniures) inhibant les tyrosine kinases et presentant des proprietes antitumorales
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
EP1238986B1 (fr) 1992-10-28 2008-06-25 Genentech, Inc. Utilisation d'antagonistes du facteur de croissance cellulaire VEGF
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9611797D0 (en) 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
EP1247803A3 (fr) * 1996-08-23 2002-10-16 Sugen, Inc. Composés d'indolinone et leur utilisation comme modulateurs de la protéine kinase
WO1998045708A1 (fr) * 1997-04-08 1998-10-15 Sugen, Inc. Etude et traitement des maladies liees a des fonctions cellulaires specifiques de proteines tyrosines kinases receptrices
ATE292623T1 (de) * 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
CA2297831A1 (fr) 1997-08-02 1999-02-11 The Procter & Gamble Company Procede utile pour preparer des tensioactifs a base d'alcool poly(alcoxyle) a coiffe d'ether
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999048868A2 (fr) * 1998-03-26 1999-09-30 Sugen, Inc. Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
NZ508815A (en) * 1998-05-29 2005-02-25 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors
KR100649925B1 (ko) * 1998-12-17 2007-02-28 에프. 호프만-라 로슈 아게 싸이클린-의존성 키나제, 특히 ｃｄｋ2 의 저해제로서4-알케닐 (및 알키닐) 옥신돌
US6689806B1 (en) * 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
CA2368041A1 (fr) * 1999-03-24 2000-09-28 Sugen, Inc. Composes d'indolinone tels que des inhibiteurs de kinase
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
EP1233943B1 (fr) * 1999-11-24 2011-06-29 Sugen, Inc. Formulations pour agents pharmaceutiques ionisables comme acides libres ou bases libres
US6339100B1 (en) 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis

Also Published As

Publication number Publication date
DE60029138D1 (de) 2006-08-10
MXPA02006263A (es) 2004-02-26
CA2395461A1 (fr) 2001-06-28
AU3436301A (en) 2001-07-03
NZ519697A (en) 2004-08-27
HK1050642A1 (en) 2003-07-04
WO2001045689A3 (fr) 2002-01-03
AU784266B2 (en) 2006-03-02
DE60029138T2 (de) 2007-06-06
EP1255536A2 (fr) 2002-11-13
WO2001045689A2 (fr) 2001-06-28
US20050288353A1 (en) 2005-12-29
US20040002534A1 (en) 2004-01-01
ES2267605T3 (es) 2007-03-16
PT1255536E (pt) 2006-09-29
CY1106165T1 (el) 2011-06-08
EP1255536B1 (fr) 2006-06-28
JP5004392B2 (ja) 2012-08-22
JP2004500363A (ja) 2004-01-08
US20020010203A1 (en) 2002-01-24
ATE331514T1 (de) 2006-07-15
US7211600B2 (en) 2007-05-01
CA2395461C (fr) 2010-05-25

Similar Documents

Publication Publication Date Title
DK1255536T3 (da) Indolinonderivater til modulation af c-kit-tyrosinproteinkinase
ATE292623T1 (de) 2-indolinonderivate als modulatoren der proteinkinase-ativität
LU92508I2 (fr) Cabozantinib et toutes les formes thérapeutiquement équivalentes qui en dérivent telles que protégées par le brevet de base, y compris les sels pharmacetuiquement acceptables
WO1995024190A3 (fr) Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
DE60206636D1 (de) THERAPEUTISCHE 1H-PYRIDO[4,3-b]INDOLE
NZ516292A (en) Pyrrolotriazine inhibitors of kinases
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
NO20023831L (no) Pyrrol substituert 2-indolinonproteinkinaseinhibitorer
CY1115124T1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
EA200200473A1 (ru) Ингибиторы тирозинкиназы
MY128449A (en) Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
IL162203A0 (en) Indolinone derivatives useful as protein inase inhibitors
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
TW200716118A (en) Aminopyrimidines as kinase modulators
TW200718693A (en) Aminopyrimidines as kinase modulators
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ